An “unprecedented” discovery: American scientists manage to cure colorectal cancer

the main thing
These are clinical trials that bring much hope in the fight against the disease of the 21st century. An American research team says an effective treatment has been found to treat colorectal cancer.

“This is the first time this has happened in the history of cancer.” Dr. Luis A. Diaz Jr. of the Memorial Sloan Kettering Cancer Center is in disbelief. He and his team were able to beat colorectal cancer in clinical trials. La prouesse medical is told in the columns du New England Journal of Medicine : For almost six months, the researchers conducted experiments using dostarlimab, a monoclonal antibody. According to the New York Timesthis treatment unmasks “cancer cells, allowing the immune system to identify and destroy them”: “These drugs do not work by directly attacking the cancer itself, but cause a person’s immune system to most of the work “, explain with NPRDr. Hanna Sanoff of the University of North Carolina

Twelve patients participated in the experiment, according to the researchers, who received a dose of the product every three weeks for six months. If the latter developed a “complete and sustained clinical response 12 months after the end of treatment”, it was no longer necessary for them to undergo chemotherapy.

“A complete clinical response”

The results are unequivocal: the 12 patients who participated in this experiment “had a complete clinical response without any signs of a tumor.” In any case, this is what MRI scans show. In addition, “no progression or recurrence was reported during follow-up,” the study said. “It’s unprecedented,” said Dr. Alan P. Venook, a colorectal cancer specialist. at the University of California, San Francisco, in the American tabloid columns. The researchers will closely monitor the 12 patients who participated in this study to “assess the duration of the immune response.”

In France, this drug is better known as “Jemperli”. The High Health Authority issued an unfavorable opinion in October 2021 on the reimbursement of this drug by Social Security: the body pointed the finger at the “lack of robust comparative data”, “the very preliminary nature of efficacy data available “, or” a higher risk premium for administering medicines whose efficacy is well-founded “.

Leave a Comment